Robert Kieszko

Efficacy and Safety of First-Line Chemoimmunotherapy with Durvalumab or Atezolizumab in Extensive-Stage of Small-Cell Lung Cancer in Real World Practice

Aleksandra Łomża-Łaba, Magdalena Knetki‐Wróblewska, Michał Gil, Paweł Krawczyk et autres

Background: Small-cell lung cancer (SCLC) is characterised by an aggressive clinical course and the early development of distant metastases.The introduction of immune checkpoint inhibitors to platinum-based chemotherapy has significantly improved survival outcomes.The aim of this study was to compare the efficacy and …

pl, hu (code pays fourni par la source)

Immune-Related Adverse Events of Checkpoint Inhibitors and Human Leukocyte Antigen System: A Review

Kamil Kośmider, Agata Kozakiewicz, Paweł Krawczyk, Robert Kieszko et autres

Kamil Kośmider,1,2 Agata Kozakiewicz,3 Paweł Krawczyk,1 Robert Kieszko,1 Katarzyna Szklener,2 Magdalena Skórzewska,2 Kamila Wojas-Krawczyk,1 Ewa Kalinka,4 Janusz Milanowski1 1Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland; 2Department of Clinical Oncology and Chemotherapy, Medical University of Lublin, Lublin, Poland; …

Immune-Related Adverse Events of Checkpoint Inhibitors and Human Leukocyte Antigen System: A Review

Kamil Kośmider, Agata Kozakiewicz, Paweł Adam Krawczyk, Robert Kieszko et autres

Abstract: The introduction of immune checkpoint inhibitors (ICIs) in the treatment of cancer has significantly improved patient outcomes. Whereas ICIs have a substantially more beneficial risk profile than chemotherapy, immune-related adverse events (irAEs) are currently among the most pressing challenges of clinical …

pl (code pays fourni par la source)

Association between gut microbiome components and immunotherapy efficacy in two small cell lung cancer cases with divergent outcomes

Anna Grenda, Ewelina Iwan, Paweł Adam Krawczyk, Izabela Chmielewska et autres

Introduction. Immunotherapy can be effective in some patients with small-cell lung cancer (SCLC) with good performance status. However, the factors contributing to sustained treatment responses remain unclear. The intestinal microbiome profile has emerged as a potential biomarker for the effectiveness of chemoimmunotherapy …

pl (code pays fourni par la source)

MA10.04 Low-Pass Wgs Reveals Clonal Evolution of CNAs Associated With Response to the First-Line Immunotherapy or Chemoimmunotherapy in NSCLC Patients

Marcin Nicoś, Natalia Galant, N. Krzyżanowska, Barbara Kuźnar-Kamińska et autres

pl (code pays fourni par la source)

P1.11.63 Shifts of Mutational Signatures Reveal Response Variability to Pembrolizumab-Based Immunotherapy in NSCLC Patients

Marcin Nicoś, Natalia Galant, N. Krzyżanowska, Barbara Kuźnar-Kamińska et autres

pl (code pays fourni par la source)

EP.13.17 Efficacy of First-Line Chemoimmunotherapy With Durvalumab or Atezolizumab in SCLC - Experiences From Practice of Two Polish Oncology Centers

Aleksandra Łomża-Łaba, Magdalena Knetki‐Wróblewska, Paweł Krawczyk, Izabela Chmielewska et autres

pl, hu (code pays fourni par la source)

MET and SLFN11 as a Players in the SCLC Molecular Subtyping Game

Anna Grenda, Natalia Galant, Aleksandra Łomża-Łaba, Paweł Adam Krawczyk et autres

The possibilities of small-cell lung cancer (SCLC) therapy were strictly limited for years, leading to high patient mortality rates. New approaches to SCLC treatment are being proposed, including chemoimmunotherapy. However, biomarkers enabling appropriate personalization of therapy in SCLC patients have not been …

pl (code pays fourni par la source)

Gut microbial predictors of first-line immunotherapy efficacy in advanced NSCLC patients

Anna Grenda, Ewelina Iwan, Barbara Kuźnar-Kamińska, Arkadiusz Bomba et autres

The composition of the gut microbiome of patients with advanced non-small cell lung cancer is currently considered a factor influencing the effectiveness of treatment with immune checkpoint inhibitors. We aimed to evaluate the baseline gut microbiome composition in patients before receiving first-line …

pl (code pays fourni par la source)

Exploring immunotherapy efficacy in non-small cell lung cancer patients with BRAF mutations: a case series and literature review

Izabela Chmielewska, Paweł Krawczyk, Magdalena Wójcik-Superczyńska, Anna Grenda et autres

Background: The use of immunotherapy in treatment of non-small cell lung cancer (NSCLC) patients with the BRAF gene mutations is an area of active research and is an item of clinical trials. While BRAF mutations are relatively infrequent in NSCLC patients, comprising …

pl (code pays fourni par la source)

Gut resistome of NSCLC patients treated with immunotherapy

Ewelina Iwan, Anna Grenda, Arkadiusz Bomba, Katarzyna Bielińska et autres

Background The newest method of treatment for patients with NSCLC (non-small cell lung cancer) is immunotherapy directed at the immune checkpoints PD-1 (Programmed Cell Death 1) and PD-L1 (Programmed Cell Death Ligand 1). PD-L1 is the only validated predictor factor for immunotherapy …

pl (code pays fourni par la source)

Genetic and geographic influence on phenotypic variation in European sarcoidosis patients

Sandra Freitag‐Wolf, Jonas C. Schupp, Björn C. Frye, Annegret Fischer et autres

Introduction: Sarcoidosis is a highly variable disease in terms of organ involvement, type of onset and course. Associations of genetic polymorphisms with sarcoidosis phenotypes have been observed and suggest genetic signatures. Methods: After obtaining a positive vote of the competent ethics committee …

de, pl, it, ro, nl, gb, cz, ie, is, hr, hu, be, fr (code pays fourni par la source)